For years, pharma marketing has measured success by traffic — sessions, page views, time on site. That model is collapsing. AI Overviews, chatbot answers, and zero-click search results mean HCPs and patients increasingly get what they need without ever landing on a pharma website. The question isn't whether this shift is coming — it's already here. So what does marketing look like when the destination disappears? This keynote confronts the uncomfortable reality that "driving traffic" may be the wrong goal entirely, and reframes success around a harder, more urgent question: is your brand the source AI systems trust enough to cite, recommend, or answer with — even when no one ever clicks through? For pharma marketers still optimizing for a web that's quietly disappearing, this is the wake-up call.
For most pharmaceutical product marketers, success is measured by product launches, market adoption, and commercial performance. Their days are spent balancing campaigns, regulatory requirements, stakeholder alignment, agency management, and increasingly complex launch timelines. Corporate brand has traditionally played only a limited role in that work.
That is beginning to change. Across the pharmaceutical industry, more organizations are investing in stronger enterprise brands, establishing centralized marketing functions, and creating greater consistency across product portfolios. While those strategic decisions are made long before implementation begins, product marketers are often the teams who experience them most directly through new governance, shared brand systems, portfolio decisions, and enterprise rollout plans.
In our experience helping large pharmaceutical organizations move these decisions into execution, we've seen where product marketing and corporate brand teams complement one another, where implementation creates friction, and what helps organizations make the shift successfully. This session will help product marketers understand why this evolution is happening, what to expect as corporate brand becomes more active, and how to leverage it to strengthen product launches, build stakeholder alignment, and maintain the distinct equity that makes individual product brands successful.
For most pharma brands, personalized content at scale means leaning on an agency partner — more capacity, more creative firepower, but also more handoffs, longer turnaround, and less control. Doug Nelson, [title] at Orasis Pharma, took a different path: building an in-house agentic AI platform designed to generate personalized content at the speed the business actually needed. In this session, Doug shares the real story behind that decision — what pushed Orasis to build rather than buy, what the platform actually does, and what changed (and what didn't) once content creation moved in-house. This isn't a pitch for AI as a cure-all; it's a candid look at the tradeoffs of ownership versus partnership, speed versus scale, and control versus capacity. For any marketer weighing whether to build their own AI capability or lean harder on external partners, this is a real-world data point, not a theory.
How merging digital engagement with syndicated data is powering precision, compliance, and smarter HCP strategies.
Pharma marketers are sitting on a goldmine of data, but it often lives in silos. This session explores how uniting digital engagement signals with syndicated datasets can unlock a true 360° view of HCP behavior. Learn how leading teams are overcoming integration challenges, ensuring compliance, and transforming raw data into actionable insights that drive precision targeting and smarter engagement strategies.
AI can now personalize content down to the individual HCP or patient — the right message, the right channel, the right moment. But precision isn't the same as empathy, and pharma marketers are running into an uncomfortable tension: the more targeted the experience, the more mechanical it can start to feel. This session digs into a question the industry hasn't fully answered — can personalization built by algorithms ever carry the warmth, nuance, and trust of genuine human connection? Or is pharma optimizing for relevance while quietly losing the thing that made engagement feel real in the first place? Expect a candid look at where AI-driven personalization is winning patients and HCPs over, where it's backfiring, and what "empathy at scale" actually requires beyond better data.
Pharma sits on more customer data than almost any other industry — prescribing data, claims data, CRM data, digital engagement data, syndicated market research. And yet ask most brand teams to describe their customer beyond a segment or a persona slide, and the answer gets vague fast. This session confronts an uncomfortable paradox: why does more data so rarely translate into more understanding? The problem isn't a lack of information — it's fragmented systems, siloed teams, and a culture built around reporting metrics rather than generating insight. Expect a hard look at where pharma's data infrastructure is actually failing its marketers, what "knowing the customer" should mean in 2026, and what it would take to turn all that data into something a brand team can actually act on.
A leadership-driven look at how the role of the field rep is being redefined by personalization and content-driven engagement — and what it takes to lead teams through that shift. Dina draws on her own leadership experience to explore how field engagement strategies must evolve alongside personalized healthcare content, and what leaders need to unlearn to get there.
Every HCP a consumer in their "other life". Those experiences reset expectations, and pharma can’t afford to lag behind and play it safe. This session will set the stage for the Consumer-Grade Imperative, challenge pharma marketers to internalize this new HCP customer context, and introduce pathways to meet these customers where they are.
Chief Marketing Office, Global Customer Excellence, Pfizer
Wayne Simmons is a commercial-focused customer experience leader within the Chief Marketing Office (CMO) of Pfizer, where he is responsible for crafting a first-of-a-kind global customer excellence strategy and leading the adoption of customer-centric ways of working within brand... Read More →
A look at how engaging researchers and lab decision-makers differs fundamentally from HCP or patient marketing — highly technical audiences, long research cycles, and trust built on data rather than emotion. A useful counterpoint for a pharma-marketing audience used to thinking about HCP/patient CX.
Mayank Agrawal is a pharmaceutical and biotech executive with over 16 years of commercial experience across global and regional markets. Currently serving as the Head of Commercial Excellence at AstraZeneca, Mayank leads commercial transformation designed to drive growth while mitigating... Read More →
Most pharma commercial models are built for scale — broad reach, broad segments, broad messaging. Rare disease brands don't have that luxury, and increasingly, that constraint is becoming an advantage. Vinícius Dantas Alves, Associate Vice President & Global Brand Lead for ASMD at Sanofi, makes the case that rare disease commercialization — where every undiagnosed patient represents a missed opportunity and every barrier removed changes a life — demands a fundamentally different playbook than mainstream pharma marketing. In this session, Vinícius explores how AI-enabled tools are helping rare disease teams find the undiagnosed, personalize outreach at the individual level, and remove access barriers with a precision that mass-market brands rarely need. For CX leaders working in larger therapeutic areas, this is a masterclass in what patient-centricity looks like when there's no room for a "good enough" segment — and why some of the sharpest commercial innovation in pharma right now is happening in rare disease, not primary care.
The life sciences industry has spent decades competing on innovation, efficacy, and access. Yet as products proliferate, information becomes ubiquitous, and AI reshapes engagement, organizations face a new question: When science is comparable, what drives confidence, trust, adoption, adherence, and loyalty? This session explores idea and provides practical approaches that experiences . . . the realities patients, clinicians, and care teams encounter across awareness, access, treatment, support, and follow-through . . . may be the most overlooked drivers of both human and business outcomes.
We face a systemic breakdown in healthcare trust, but the solution isn't just a technology fix—it's a Customer Experience (CX) intervention. This talk operationalizes the Digital Trust Economy, transforming the complex problem of provider-patient friction into a unified, high-value experience that fuels engagement and loyalty for both HCPs and patients.
Omnichannel engagement in pharma has evolved far beyond simply coordinating messages across channels—it’s now about delivering truly personalized experiences that meet HCPs and patients where they are. This session explores the latest trends, technologies, and strategies shaping omnichannel execution, from AI-powered orchestration to data-driven insights that inform content and timing. Learn how to break down silos, create seamless journeys, and measure the impact of integrated campaigns that resonate on a personal level. Discover how organizations are transforming omnichannel from a tactical approach into a strategic driver of engagement and loyalty.
